Cost-effectiveness of PARP inhibitors in malignancies: A systematic review

Abstract

Objectives Poly (ADP-ribose) polymerase inhibitor (PARPi) have become a mainstay for the treatment of BRCA-mutant malignancies. PARPis are likely to be more effective but also bring an increase in costs. Thus, we aimed at evaluating the cost effectiveness of PARPis in the treatment of malignancies. Methods Studies of cost effectiveness of PARPis were searched from PubMed, Web of Science, and Cochrane Library. Key information was extracted from the identified studies and reviewed. Quality of the included studies was evaluated using Quality of Health Economic Studies (QHES) instrument. Modeling techniques, measurement of parameters and uncertainty analysis were analyzed across studies. Interventions and cost-effectiveness results were reported stratified by patient population. Results Among the 25 studies identified, we included 17 on ovarian cancer, 2 on breast cancer, 3 on pancreatic cancer, and 3 on prostate cancer that involved olaparib, niraparib, rucaparib, and talazoparib. All studies had a QHES score of above 75. In the maintenance therapy of ovarian cancer, additional administration of olaparib was cost-effective for newly diagnosed patients after first-line platinum-based chemotherapy but was not cost-effective for platinum-sensitive recurrent patients in majority studies. However, the economic value of other PARPis in ovarian cancer as well as all PARPis in other tumors remained controversial. Cost-effectiveness of PARPi was primarily impacted by the costs of PARPi, survival time, health utility and discount rate. Moreover, genetic testing improved the cost-effectiveness of PARPi treatment. Conclusions PARPi is potentially cost-effective for patients with ovarian, pancreatic, or prostate cancer. Genetic testing can improve the cost-effectiveness of PARPi.

PARP Inhibitors in Breast and Ovarian Cancer

“…A systematic review conducted by Haiying et al reviewed 25 papers (17 on ovarian cancers, 3 on pancreatic cancer, 3 on prostate cancer and 2 on breast cancer) on the cost-effectiveness of the use of PARPI. PARPIs that were involved in the study included olaparib, rucaparib, talazoparin and niraparib [ 106 ]. The majority of the studies demonstrated the cost-effectiveness of olaparib in the setting of newly diagnosed patients after first-line platinum-based therapy; however, cost-effectiveness was reduced in patients with platinum-sensitive recurrences.…”